Medicus Pharma aims to achieve clinical and regulatory milestones
MDCX Medicus Pharma Ltd
$0.10 -36.39%
View chart & analysis → - 1Medicus Pharma is advancing clinical and regulatory milestones and pursuing licensing and co-development opportunities.
- 2The US FDA has approved the initiation of SKNJCT-005, a registrational study for patients with Gorlin syndrome.
- 3Medicus Pharma has secured approximately $90 million in funding through equity and debt financing since its inception.
So what's the key point?
Medicus Pharma is now able to start a new study involving patients in the US. The company has raised about $90 million to fund its operations so far.
Source Proactive +1 · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.